Weekly Top News – Psoriasis – June 15, 2020

June 15, 2020

 Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Sun Pharma announces long-term insights into the clinical use of Ilumya (tildrakizumab-asmn) in a cross section of people living with moderate-to-severe plaque psoriasis (PRNewswire) – Jun 12, 2020 – “Sun Pharmaceutical Industries Ltd…announced that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020….Long-term analyses of the reSURFACE 1 and 2 extension studies found that Ilumya offers sustained and improved results in patients with moderate-to-severe plaque psoriasis….Another post-hoc analysis…saw continued improvement and sustained response rates when they maintained treatment for up to three years….A 10-year cost analysis study revealed that ILUMYA is among the most cost-effective first-line therapies….’Notably, 85 percent of the patients included in our analysis had never used a biologic before even though they have been living with psoriasis for over a decade,” said lead investigator Kim Papp, M.D., Ph.D….”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim; Cosentyx (secukinumab) / Novartis
AbbVie presents new late-breaking data showing Skyrizi (risankizumab-rzaa) achieves superior rates of complete skin clearance versus Cosentyx (secukinumab) at 52 weeks (PRNewswire) – Jun 12, 2020 – P3, N=327; NCT03478787; Sponsor: AbbVie; “AbbVie…today announced new late-breaking phase 3b head-to-head data showing superior rates of skin clearance for Skyrizi (risankizumab-rzaa) to Cosentyx (secukinumab) at week 52…66 percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in the Psoriasis Area and Severity Index (PASI 100)—versus 40 percent of patients receiving Cosentyx at week 52 (p

 

Stelara (ustekinumab) / J&J; bimekizumab (UCB4940) / UCB
First presentations of bimekizumab phase 3 data demonstrate superior skin clearance over placebo and Stelara at week 16 in adults with moderate-to-severe plaque psoriasis (PRNewswire) – Jun 12, 2020 – P3, N=435; BE READY (NCT03410992); P3, N=570; BE VIVID (NCT03370133); Sponsor: UCB Biopharma S.P.R.L.; “UCB…announced the first presentations of data from the Phase 3 clinical development program of bimekizumab…as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting….’Today’s results demonstrate that bimekizumab may offer rapid and consistent skin clearance results over the course of 12 months, which represents a profound and meaningful evolution for many people living with psoriasis,’ said Dr. Kenneth Gordon…Phase 2b data from the BE ABLE 2 psoriasis study will also be presented virtually for AAD 2020….The two late-breaking presentations cited in this release are…Kim A. Papp, Andrew Blauvelt, Richard Langley…Kenneth Gordon…Mark Lebwohl.”

 

Humira (adalimumab) / Eisai, AbbVie; Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim; Stelara (ustekinumab) / J&J
Abbvie’s psoriasis drug proves long-term treatment effect (Korea Biomedical Review) – Jun 10, 2020 – P=NA, N=NA; “Abbvie’s Skyrizi (ingredient: risankizumab) showed the best treatment efficacy and lasting effect on plaque psoriasis patients among existing biological products, Professor Youn Sang-woong of the Seoul National University Bundang Hospital said Wednesday….In a long-term study that compared Skyrizi and Stelara (ingredient: ustekinumab) and Humira (ingredient: adalimumab), researchers confirmed that the proportion of patients who achieved Psoriasis Area Severity Index (PASI) 90 at week 16 of treatment reached 75-90 percent.”

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Sun Pharma plans to present clinical insights from 25 data abstracts across its dermatology portfolio at the 2020 AAD virtual meeting experience (PRNewswire) – Jun 11, 2020 – “Sun Pharmaceutical Industries Inc., USA (SPII) ‘Sun Pharma’ today announced 25 data abstracts from its dermatology portfolio will be presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. The data presentations will highlight key clinical insights on Ilumya…The virtual meeting will take place from June 12 to June 14, 2020.”

 

Taltz (ixekizumab) / Eli Lilly, Second Xiangya Hospital of Central South University; Olumiant (baricitinib) / Incyte, Eli Lilly, University of Colorado; mirikizumab (LY3074828) / Eli Lilly
Lilly highlights the evolution of its dermatology portfolio at Annual American Academy of Dermatology Meeting (AAD) (PRNewswire) – Jun 12, 2020 – “Eli Lilly and Company…announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting. The data being highlighted at this year’s virtual conference include the latest therapeutic data available in dermatological conditions such as psoriasis and atopic dermatitis (AD). Lilly will present 24 e-Posters, including 14 for Taltz, five for baricitinib, three for mirikizumab and two for lebrikizumab…e-Posters…Presenting Authors: Mark Lebwohl, Andrew Blauvelt…Kim Papp…”

 

Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
LEO Pharma presents results from study of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) foam for topical use in long-term maintenance treatment of plaque psoriasis (Businesswire) – Jun 12, 2020 – P3, N=650; PSO-LONG (NCT02899962); Sponsor: LEO Pharma; “LEO Pharma…presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar; (calcipotriene and betamethasone dipropionate) Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.3,4 Results were presented as ePosters online at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020….Enstilar (calcipotriene and betamethasone dipropionate) Foam met the primary endpoint in the PSO-LONG trial by prolonging time to first relapse versus foam vehicle (56 days vs. 30 days)…These results, as demonstrated by the primary endpoint, introduce new clinical data for the treatment of adult patients with plaque psoriasis,’ said Mark Lebwohl, M.D.”

 

AK111 / Akesobio
The first patient of Kangfang Biological (09926-HK) new drug AK111 was successfully enrolled [Google translation] (Finet Group) – Jun 7, 2020 – “Kangfang Bio-B (09926-HK) announced that…drug AK111…in the first phase 1b clinical trial in China, the first case of moderate to severe plaque psoriasis…patient has successfully completed enrollment and administration….AK111 has previously received IND approval for psoriasis in China…completed a phase I study on healthy subjects…safe and well tolerated at a single dose…currently conducting clinical studies of multiple dosing in patients with moderate to severe psoriasis in China.”

 

BMS-986165 / BMS
POETYK-PSO-2: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) – Jun 9, 2020 – P3; N=1000; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Trial completion date: Jul 2020 –> Dec 2020; Trial primary completion date: Jul 2020 –> Dec 2020

 

Enbrel (etanercept) / Pfizer, Amgen
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO). (clinicaltrials.gov) – Jun 11, 2020 – P; N=1; Not yet recruiting; Sponsor: Pfizer

No Comments

Post a Comment

Comment
Name
Email
Website